Clinical trials: Clozapine Resistant Schizophrenia, active
Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine
Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug Monitoring
The goal of this observational study is to better understand how clozapine treatment can be tailored as regards minimizing side effects and optimizing efficacy and monitoring.
- Conditions
- Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine, General Side Effects of Clozapine, Constipation Due to Clozapine
- Trial name
- COTTONS (NCT06749041)
- Volunteers
- 60 people
- Sponsor
- GGZ Noord-Holland-Noord
Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine
No Guts No Glory Probiotics
The goal of this clinical trial is to learn if probiotics work to prevent or reduce metabolic side effects caused by antipsychotic medication in adults.
- Trial name
- NGNGP (NCT07606014)
- Testing
- Probiotic Formula
- Where
- 3 sites in Netherlands
- Volunteers
- 112 people
- Sponsor
- University Medical Center Groningen
Treatment-resistant Schizophrenia
Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
The goal of this study is to optimize treatment strategies for Chinese patients with treatment-resistant schizophrenia (TRS). It will compare two types of treatment: 1.
- Trial name
- STATRS (NCT07918222)
- Testing
- [Phase 1] Clozapine, [Phase 1] Aripiprazole, [Phase 1] Amisulpride
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Treatment Resistant Schizophrenia
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current…
- Trial name
- MECT-RESIST (NCT06456983)
- Testing
- maintenance electroconvulsive therapy (mECT)
- Where
- 14 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Schizophrenia and Related Disorders, Early Treatment-Resistance
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros.
- Trial name
- INTENSIFY SZ (NCT05958875)
- Testing
- Clozapine, Second-line Antipsychotics (treatment as usual)
- Where
- 13 sites in Austria, Germany and 3 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Treatment Resistant Schizophrenia, Obesity & Overweight
Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects
The primary objective of the study is to assess the efficacy and tolerability of a 90-day daily supplementation with a Nitraria retusa dried crushed leaves infusion on the iatrogenic metabolic side effects induced in patients…
- Conditions
- Treatment Resistant Schizophrenia, Obesity & Overweight, Abdominal Obesity
- Trial name
- NCT07817069
- Testing
- The Nitraria retusa arm
- Where
- Tunisia
- Volunteers
- 30 people
- Sponsor
- Faculty of Medicine, Sousse